Currently out of the existing stock ratings of Graham Perry, 8 are a BUY (42.11%), 9 are a HOLD (47.37%), 2 are a SELL (10.53%).
Analyst Graham Perry, currently employed at BAML, has had 75% of price targets met with an average potential upside of 49.97%, reached in 2100 days on average.
Graham Perry has documented 29 price targets and ratings displayed on 4 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on GSK, GlaxoSmithKline PLC ADR at 24-Jul-2026.
Analyst best performing recommendations are on NVS (NOVARTIS AG ADR).
The best stock recommendation documented was for NVS (NOVARTIS AG ADR) on 10/4/2023. The price target of $118 was fulfilled within 636 days with a profit of $31.31 (36.12%), with a performance score of 0.57.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 30-Oct-2026
17 days ago
(30-Oct-2026)
2/2 (100%)
$25.04 (27.08%)
407
Sell Since 10-Sep-2026
$136
$-24.5 (-15.26%)
2 months 6 days ago
(10-Sep-2026)
1/2 (50%)
$-1.48 (-1.08%)
171
Buy Since 26-Mar-2026
$170
$9.5 (5.92%)
$109
7 months 21 days ago
(26-Mar-2026)
6/7 (85.71%)
$20.3 (13.56%)
672
Hold Since 11-Mar-2026
$180
$33.97 (23.26%)
$105
8 months 5 days ago
(11-Mar-2026)
1/2 (50%)
$24.2 (15.53%)
1814
Hold Since 07-Oct-2024
$180
$19.5 (12.15%)
$125
8 months 30 days ago
(17-Feb-2026)
7/8 (87.5%)
$18.74 (11.62%)
1318
Which stock is Graham Perry most bullish on?
What Year was the first public recommendation made by Graham Perry?